Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1636, 2008-01, pp. : 2-2
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Sevelamer could be worth it in hyperphosphataemia
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 552, 2008-01 ,pp. :
ESRD with hyperphosphataemia: an economic burden
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 505, 2006-01 ,pp. :
Compounds in development to combat hyperphosphataemia
Expert Opinion on Investigational Drugs, Vol. 10, Iss. 12, 2001-12 ,pp. :
PEG IFN- -2b + ribavirin: 12 weeks' worth could do the trick in HCV
Inpharma, Vol. 1, Iss. 1494, 2005-01 ,pp. :